SPA
MGNX icon

Sherbrooke Park Advisers’s MacroGenics MGNX Stock Holding History

Sherbrooke Park Advisers’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,219
Closed -$98.9K – 601
2023
Q3 		$98.9K Buy
+21,219
New +$106K 0.03% 452

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Sherbrooke Park Advisers's MGNX Position: Q4 2023 in Review

Sherbrooke Park Advisers sold out of MacroGenics (MGNX) in Q4 2023, closing a stake of 21,219 shares — an estimated $98.9K sold.

Sherbrooke Park Advisers first reported a position in MGNX in Q3 2023 and held it in 1 quarter. The position peaked at $98.9K in Q3 2023. 142 funds tracked by Wall St. Rank hold MGNX as of Q4 2023.

  • Sherbrooke Park Advisers reported no remaining MacroGenics position as of Q4 2023 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 21,219 MacroGenics shares in Q4 2023, an estimated $98.9K.
  • Sherbrooke Park Advisers first reported a position in MacroGenics in Q3 2023 and held it in 1 quarter.
  • Sherbrooke Park Advisers's MacroGenics position peaked at $98.9K in Q3 2023.
  • 142 funds tracked by Wall St. Rank held MacroGenics as of Q4 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.